Drug Profile
Osocimab - Bayer HealthCare
Alternative Names: BAY-1213790; FXIa antibodyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Aronora; Bayer HealthCare
- Developer Bayer HealthCare
- Class Antibodies; Anticoagulants; Monoclonal antibodies
- Mechanism of Action Factor XIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arterial thrombosis; Venous thromboembolism; Venous thrombosis
Most Recent Events
- 02 Dec 2022 Discontinued - Phase-I for Arterial thrombosis in Germany (IV) (Bayer Healthcare pipeline, December 2022)
- 02 Dec 2022 Discontinued - Phase-I for Venous thromboembolism in Belgium, USA, Portugal (IV) (Bayer Healthcare pipeline, December 2022)
- 02 Dec 2022 Discontinued - Phase-I for Venous thrombosis in Germany (IV) (Bayer Healthcare pipeline, December 2022)